Knockdown of long non‑coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells

Fan,Heng; Zhu,Jian‑Hua; Yao,Xue‑Qing

doi:10.3892/mmr.2018.8907

Knockdown of long non‑coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells

Authors:
- Heng Fan
- Jian‑Hua Zhu
- Xue‑Qing Yao
View Affiliations

Affiliations: The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Intensive Care Unit, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China
Published online on: April 20, 2018 https://doi.org/10.3892/mmr.2018.8907
Pages: 8309-8315
Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) is one of the primary causes of chemotherapy failure in colorectal cancer (CRC), and extensive biological studies into MDR are required. The non‑coding RNA plasmacytoma variant translocation 1 (PVT1) has been demonstrated to be associated with low survival rates in patients with CRC. However, whether PVT1 serves a critical function in the MDR of CRC remains to be determined. To determine the association between PVT1 expression and 5‑fluorouracil (5‑FU) resistance in CRC, the expression levels of PVT1 mRNA in 5‑FU‑resistant CRC tissues and cell lines (HCT‑8/5‑FU and HCT‑116/5‑FU) were assessed by a reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Cytotoxicity was evaluated using a Cell Counting Kit‑8 assay and apoptosis rates were assessed via flow cytometry. In the present study, PVT1 mRNA was highly expressed in 5‑FU‑resistant CRC tissues and cell lines. HCT‑8/5‑FU and HCT‑116/5‑FU cells transfected with small interfering RNA PVT1 and treated with 5‑FU exhibited higher apoptotic rates and lower survival rates. By contrast, overexpression of PVT1 in HCT‑8 and HCT‑116 cells transfected with lentiviral vector‑PVT1‑green fluorescent protein and treated with 5‑FU exhibited lower apoptosis rates and higher survival rates. RT‑qPCR and western blotting demonstrated that the overexpression of PVT1 increased the mRNA and protein expression levels of multidrug resistance‑associated protein 1, P‑glycoprotein, serine/threonine‑protein kinase mTOR and apoptosis regulator Bcl2. The present study indicates that PVT1 overexpression may promote MDR in CRC cells, and suggested that inhibition of PVT1 expression may be an effective therapeutic strategy for reversing MDR in CRC.

View Figures

View References

1	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
2	Xu M, Chen YM, Huang J, Fang YJ, Huang WQ, Yan B, Lu MS, Pan ZZ and Zhang CX: Flavonoid intake from vegetables and fruits is inversely associated with colorectal cancer risk: A case-control study in China. Br J Nutr. 116:1275–1287. 2016. View Article : Google Scholar : PubMed/NCBI
3	Rebucci M and Michiels C: Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 85:1219–1226. 2013. View Article : Google Scholar : PubMed/NCBI
4	Beck-Engeser GB, Lum AM, Huppi K, Caplen NJ, Wang BB and Wabl M: Pvt1-encoded microRNAs in oncogenesis. Retrovirology. 5:42008. View Article : Google Scholar : PubMed/NCBI
5	Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, Li BS and Yang SM: The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett. 360:119–124. 2015. View Article : Google Scholar : PubMed/NCBI
6	Liu E, Liu Z and Zhou Y: Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. Int J Clin Exp Pathol. 8:3803–3810. 2015.PubMed/NCBI
7	Paci P, Colombo T and Farina L: Computational analysis identifies a sponge interaction network between long non-coding RNAs and messenger RNAs in human breast cancer. BMC Syst Biol. 8:832014. View Article : Google Scholar : PubMed/NCBI
8	Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, Tan C, Ni SJ, Dong L, Yang Y, et al: A positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res. 23:2071–2080. 2017. View Article : Google Scholar : PubMed/NCBI
9	Fang XY, Pan HF, Leng RX and Ye DQ: Long noncoding RNAs: Novel insights into gastric cancer. Cancer Lett. 356:357–366. 2015. View Article : Google Scholar : PubMed/NCBI
10	Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, Kobayashi E, Yoshikawa M, Uzawa K, Ueda S, Tanzawa H and Sato N: Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol. 40:1005–1010. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wang Y, Zhou J, Wang Z, Wang P and Li S: Upregulation of SOX2 activated LncRNA PVT1 expression promotes breast cancer cell growth and invasion. Biochem Biophys Res Commun. 493:429–436. 2017. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Farhana L, Antaki F, Anees MR, Nangia-Makker P, Judd S, Hadden T, Levi E, Murshed F, Yu Y, Van Buren E, et al: Role of cancer stem cells in racial disparity in colorectal cancer. Cancer Med. 5:1268–1278. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wu Q, Yang Z, Nie Y, Shi Y and Fan D: Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 347:159–166. 2014. View Article : Google Scholar : PubMed/NCBI
15	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
16	Iden M, Fye S, Li K, Chowdhury T, Ramchandran R and Rader JS: The lncRNA PVT1 contributes to the cervical cancer phenotype and associates with poor patient prognosis. PLoS One. 11:e01562742016. View Article : Google Scholar : PubMed/NCBI
17	Zhou Q, Chen J, Feng J and Wang J: Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumour Biol. 37:3105–3113. 2016. View Article : Google Scholar : PubMed/NCBI
18	Kong R, Zhang EB, Yin DD, You LH, Xu TP, Chen WM, Xia R, Wan L, Sun M, Wang ZX, et al: Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer. 14:822015. View Article : Google Scholar : PubMed/NCBI
19	Liu E, Liu Z, Zhou Y, Mi R and Wang D: Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med. 8:20565–20572. 2015.PubMed/NCBI
20	Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD and Wang ZX: Long non-coding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol Cancer Ther. 15:1082–1094. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zhang XW, Bu P, Liu L, Zhang XZ and Li J: Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun. 462:227–232. 2015. View Article : Google Scholar : PubMed/NCBI
22	Duarte N, Varga A, Cherepnev G, Radics R, Molnár J and Ferreira MJ: Apoptosis induction and modulation of P-glycoprotein mediated multidrug resistance by new macrocyclic lathyrane-type diterpenoids. Bioorg Med Chem. 15:546–554. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wobst I, Ebert L, Birod K, Wegner MS, Hoffmann M, Thomas D, Angioni C, Parnham MJ, Steinhilber D, Tegeder I, et al: R-flurbiprofen traps prostaglandins within cells by inhibition of multidrug resistance-associated protein-4. Int J Mol Sci. 18:pii: E68. 2016. View Article : Google Scholar : PubMed/NCBI
24	Wang MZ, Qiu CZ, Yu WS, Guo YT, Wang CX and Chen ZX: GOLPH3 expression promotes the resistance of HT29 cells to 5-fluorouracil by activating multiple signaling pathways. Mol Med Rep. 17:542–548. 2018.PubMed/NCBI
25	Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, et al: Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 110:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
26	Weerasinghe P, Hallock S, Tang SC, Trump B and Liepins A: Sanguinarine overcomes p-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1,000 cells. Exp Toxicol Pathol. 58:21–30. 2006. View Article : Google Scholar : PubMed/NCBI
27	Xie Y, Yu N, Chen Y, Zhang K, Ma HY and Di Q: HMGB1 regulates P-glycoprotein expression in status epilepticus rat brains via the RAGE/NF-κB signaling pathway. Mol Med Rep. 16:1691–1700. 2017. View Article : Google Scholar : PubMed/NCBI
28	Gottesman MM and Pastan IH: The role of multidrug resistance efflux pumps in cancer: Revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene. J Natl Cancer Inst. 107:pii: djv222. 2015. View Article : Google Scholar : PubMed/NCBI
29	Yan LH, Wei WY, Cao WL, Zhang XS, Xie YB and Xiao Q: Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance. Am J Cancer Res. 5:321–332. 2014.PubMed/NCBI